ImmunOs Therapeutics Raises $11M in Series C Funding

ImmunOs Therapeutics, a Schlieren, Switzerland-based biopharmaceutical company developing HLA-based technology platform, raised $11M in Series C funding.

The round wad led by Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures as well as other existing investors. In conjunction with the round, Steve Tregay, PhD, Managing General Partner of Mission BioCapital, has joined the Company’s Board of Directors.

The company intends to sue the capital to further fund the ongoing clinical trial of its lead program IOS-1002 to completion of the Phase Ia dose escalation clinical trial as a monotherapy and in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

Led by Reinhard Ambros, Executive Chairman, ImmunOs Therapeutics leverages its immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases. ImmunOs’ lead program is a multi-functional HLA-fusion protein that binds specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and can stimulate both the innate and the adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs is also developing different modalities to agonize receptors for the modulation of the immune system in autoimmune diseases.

FinSMEs

17/09/2024